Cytokines are crucial mediators of innate and adaptive antitumor immunity and have the potential to enhance immunotherapeutic approaches to treat cancer. However, their use as therapeutics has been limited by complex biology, cytokine pleiotropy, poor drug-like properties, and severe dose-limiting toxicities. A variety of engineering approaches are emerging to improve the safety and effectiveness of cytokine therapeutics. Coupled with the development of immune checkpoint inhibitors and combination immunotherapies, interest in the use of engineered cytokines as therapeutics is rapidly progressing preclinically and clinically. This symposium will cover late breaking research in the field of cytokine biology and engineering for cancer immunotherapy.
Join us on Tuesday, November 1st starting at 8:00 PST / 11:00 EST.
Jonathan Sockolosky, Katherine Harris, Pam Borghardt, and Janice Reichert